Relay Therapeutics Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an estrogen receptor α (ERα; ESR1)-targeting moiety.

Bayer AG has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer and achondroplasia.

Amyloid Solution Inc. has disclosed microtubule-associated protein tau (PHF-tau; MAPT) and/or...

Bioversys AG has described 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivatives with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors reported to be useful for the treatment of bacterial infections and skin inflammation.

Scripps Research Institute has divulged compounds reported to be useful for the treatment of malaria.

Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) ligase binding moiety covalently bonded to a histone deacetylase (HDAC) targeting moiety through a linker.

Medshine Discovery Inc. has synthesized amino-substituted heteroaryl derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Gilead Sciences Inc. has disclosed compounds reported to be useful for the treatment of HIV infection.

Anhorn Medicines Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising E3 ubiquitin ligase binding moieties covalently linked to androgen receptor (AR)-binding moieties through a linker.